Peptide Docket
Regulatory IntelligenceGet the brief
Home//Tirzepatide
Draft — not yet published. This page is part of the planned set but is set to noindex pending editorial expansion and clinical review. Facts below are limited to what we can source today; we do not publish prices, dosing, or sourcing.

Tirzepatide vs Retatrutide

Tirzepatide: FDA-approved medicine · brand-name product is the approved route.
Retatrutide: investigational (Phase III) · not FDA-approved · not eligible for compounding.

Tirzepatide is a dual GIP/GLP-1 receptor agonist and an FDA-approved medicine (brands include Mounjaro and Zepbound).

Retatrutide is an investigational triple receptor agonist (GIP/GLP-1/glucagon) in late-stage clinical trials. It is not approved by the FDA.

A full side-by-side comparison (mechanism, evidence, status) is pending editorial expansion and clinical review.

Medical & editorial disclaimer. This article is independent reference information, not medical advice. Use any medicine only under the care of a licensed clinician. Peptide Docket is not affiliated with the FDA and does not sell medicines.